Biotech Values

[DewDiligence]

AUTL IPOs 10.12M* shares @$17.00:

https://endpts.com/autolus-extends-the-biotech-ipo-hot-streak-adding-150m-and-bringing-2-day-tally-to-718m

The UK-based Autolus was spun out of the lab of Martin Pule at University College London with some binding technology that they say can give them a safer approach to targeting CD19, along with BCMA and TACI programs in the works where they plan to leap past the current pioneers in blood cancers while expanding their reach into solid tumors.

*Assuming exercise of underwriter’s option.